/IBRX
IBRX Stock - ImmunityBio, Inc.
Healthcare|BiotechnologyNASDAQ
$2.08-0.48%
$0.01 (-0.48%) • Dec 19
68
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.11
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+188.5%upside
Target: $6.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IBRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.06 – $2.10
TARGET (TP)$6.00
STOP LOSS$1.91
RISK/REWARD1:23.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.06
52W High$4.27
52W Low$1.83
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $14.74M | $622,000 | $240,000 | $934,000 | $605,000 |
| Gross Profit | $14.74M | $622,000 | $240,000 | $934,000 | $605,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-344,182,000 | $-362,250,000 | $-351,298,000 | $-330,280,000 | $-220,880,000 |
| Net Income | $-413,564,000 | $-583,196,000 | $-416,567,000 | $-346,790,000 | $-221,851,000 |
| Net Margin | -2804.8% | -93761.4% | -173569.6% | -37129.6% | -36669.6% |
| EPS | $-0.59 | $-1.15 | $-1.04 | $-0.89 | $-0.59 |
Company Overview
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
75%
Hold / Neutral
1
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish1 Neutral/Bearish
Price Targets
$6
Average Target
↑ 198.1% Upside
Now
$4
Low
$6
Average
$8
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 20th 2025 | Piper Sandler | Upgrade | Overweight | $5 |
| March 6th 2025 | H.C. Wainwright | Initiation | Buy | $8 |
| January 10th 2025 | BTIG Research | Initiation | Buy | $6 |
| May 12th 2023 | Piper Sandler | Downgrade | Neutral | $4← $10 |
| August 3rd 2022 | Jefferies | Initiation | Buy | $8 |
Earnings History & Surprises
IBRXBeat Rate
22%
Last 18 quarters
Avg Surprise
-7.3%
EPS vs Estimate
Beats / Misses
4/11
3 met exactly
Latest EPS
$-0.07
Q4 2025
EPS Surprise History
Q1 24
-5.6%
$-0.19vs$-0.18
Q2 24
-25.0%
$-0.20vs$-0.16
Q3 24
-17.6%
$-0.20vs$-0.17
Q4 24
+22.2%
$-0.14vs$-0.18
Q1 25
+42.3%
$-0.15vs$-0.26
Q2 25
-25.0%
$-0.15vs$-0.12
Q3 25
0.0%
$-0.10vs$-0.10
Q4 25
+30.0%
$-0.07vs$-0.10
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $-0.08 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.10 | $-0.07 | +30.0% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.10 | $-0.10 | 0.0% | = MET |
Q2 2025 | May 12, 2025 | $-0.12 | $-0.15 | -25.0% | ✗ MISS |
Q1 2025 | Mar 3, 2025 | $-0.26 | $-0.15 | +42.3% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.18 | $-0.14 | +22.2% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.17 | $-0.20 | -17.6% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.16 | $-0.20 | -25.0% | ✗ MISS |
Q1 2024 | Mar 19, 2024 | $-0.18 | $-0.19 | -5.6% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.27 | $-0.19 | +29.6% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.26 | $-0.28 | -7.7% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.27 | $-0.27 | 0.0% | = MET |
Q1 2023 | Mar 1, 2023 | $-0.22 | $-0.27 | -22.7% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.23 | $-0.28 | -21.7% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-0.24 | $-0.24 | 0.0% | = MET |
Q2 2022 | May 10, 2022 | $-0.22 | $-0.26 | -18.2% | ✗ MISS |
Q1 2022 | Mar 2, 2022 | $-0.21 | $-0.23 | -9.5% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-0.20 | $-0.22 | -10.0% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.12 | $-0.23 | -91.7% | ✗ MISS |
Latest News
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $24 Price Target
📈 PositiveBenzinga•Dec 16, 2025, 06:05 PM
ImmunityBio Treatment With ANKTIVA Plus Bacillus Calmette-Guerin Shows Efficacy At 12, 36 Months
📈 PositiveBenzinga•Dec 16, 2025, 02:06 PM
Jefferies Maintains Buy on ImmunityBio, Raises Price Target to $9
📈 PositiveBenzinga•Dec 12, 2025, 06:59 PM•Also:
ImmunityBio shares are trading higher after the company announced that the European Medicines Agency has recommended granting a conditional marketing authorization in the EU for ANKTIVA in combination with BCG for the treatment of BCG-unresponsive NMIBC carcinoma in situ.
📈 PositiveBenzinga•Dec 12, 2025, 06:38 PM
ImmunityBio, Novo, Moderna among winners of EU drug recommendations this week
📈 PositiveSeeking Alpha•Dec 12, 2025, 03:45 PM•Also:
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $24 Price Target
📈 PositiveBenzinga•Dec 12, 2025, 12:45 PM
ImmunityBio's Cancer Therapy Clears Major EU Hurdle, Opening Door To Earlier Access For Thousands Of Patients
📈 PositiveBenzinga•Dec 12, 2025, 11:11 AM
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $24 Price Target
📈 PositiveBenzinga•Dec 11, 2025, 12:39 PM
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $24 Price Target
📈 PositiveBenzinga•Nov 13, 2025, 06:26 PM
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $24 Price Target
📈 PositiveBenzinga•Nov 5, 2025, 02:00 PM
ImmunityBio Q3 EPS $(0.07) Beats $(0.10) Estimate, Sales $32.061M Beat $31.880M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 06:48 AM
HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $8 Price Target
📈 PositiveBenzinga•Sep 10, 2025, 10:57 AM
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $24 Price Target
📈 PositiveBenzinga•Sep 8, 2025, 02:11 PM
ImmunityBio Announces Paradigm Changing Findings From Phase 2 QUILT-3.055 Study, Showing ANKTIVA Reverses Lymphopenia In Patients With Checkpoint Inhibitor-Resistant Advanced NSCLC, With Reversal Resulting In Significant Prolonged mOS
📈 PositiveBenzinga•Sep 8, 2025, 12:35 PM
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $24 Price Target
📈 PositiveBenzinga•Aug 26, 2025, 04:26 PM
ImmunityBio shares are trading higher after the company announced its chemotherapy-free combo showed 100% disease control results and is planning a Phase 2 trial.
📈 PositiveBenzinga•Aug 26, 2025, 12:57 PM
ImmunityBio's Chemotherapy-Free Combo Shows 100% Disease Control In Early Glioblastoma Trial, Plans Phase 2
📈 PositiveBenzinga•Aug 26, 2025, 12:34 PM
IBRX stock has given up its prior gain. ImmunityBio shares were trading higher after the company announced it has opened a new Phase 2 study to assess the BioShield platform.
➖ NeutralBenzinga•Aug 21, 2025, 12:39 PM
ImmunityBio shares are trading higher after the company announced it has opened a new Phase 2 study to assess the BioShield platform.
📈 PositiveBenzinga•Aug 21, 2025, 12:09 PM
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $24 Price Target
📈 PositiveBenzinga•Aug 19, 2025, 02:47 PM
Frequently Asked Questions about IBRX
What is IBRX's current stock price?
ImmunityBio, Inc. (IBRX) is currently trading at $2.08 per share. The stock has moved -0.48% today.
What is the analyst price target for IBRX?
The average analyst price target for IBRX is $6.00, based on 1 analyst.
What sector is ImmunityBio, Inc. in?
ImmunityBio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IBRX's market cap?
ImmunityBio, Inc. has a market capitalization of $2.05 billion, making it a mid-cap company.
Does IBRX pay dividends?
No, ImmunityBio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGIO
Agios Pharmaceuticals, Inc.
$24.46
Mkt Cap: $1.4B
BEAM
Beam Therapeutics Inc.
$26.57
Mkt Cap: $2.7B
COGT
Cogent Biosciences, Inc.
$39.55
Mkt Cap: $5.6B
DNLI
Denali Therapeutics Inc.
$16.85
Mkt Cap: $2.5B
ETNB
89bio, Inc.
$14.84
Mkt Cap: $2.2B
GLPG
Galapagos N.V.
$32.36
Mkt Cap: $2.1B
LQDA
Liquidia Corporation
$34.53
Mkt Cap: $3.0B
RCUS
Arcus Biosciences, Inc.
$21.98
Mkt Cap: $2.4B
RXRX
Recursion Pharmaceuticals, Inc.
$4.26
Mkt Cap: $1.7B
VRDN
Viridian Therapeutics, Inc.
$31.92
Mkt Cap: $2.6B
Explore stocks similar to IBRX for comparison